Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Recombinant Mouse IFN-beta Protein

Catalog No.: RP01872 Recombinant

Sequence Information

Species	Gene ID	Swiss Prot
Mouse	15977	P01575

Tags
C-6*His

Synonyms
Interferon beta; IFN-beta; Ifnb1; Ifb; Ifnb

Product Information

Source
HEK293 cells

Purification
≥ 90% as determined by SDS-PAGE.

Calculated MW
20.57 kDa

Observed MW
30-40 kDa

Endotoxin
< 1 EU/μg of the protein by LAL method.

Formulation
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

Reconstitution
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Background

Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

Basic Information

Description
Recombinant Mouse IFN-beta Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ile22-Asn182) of Mouse IFN-beta (Accession #NP_034640.1.) fused with His tag at the C-terminus.

Bio-Activity

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Storage
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Avoid repeated freeze/thaw cycles.

Operational Notes
For your safety and health, please wear a lab coat and disposable gloves for handling.

* □□□□□□□□□□□□□□□□□□□□□□□□□□□□

Validation Data



Recombinant Mouse IFN-beta Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.

For research use only. Not for therapeutic or diagnostic purposes.
Please visit http://abclonal.com for a complete listing of recommended products.